Log in

Relevant bibliographies by topics / Ischaemic heart disease / Journal articles

Journal articles on the topic 'Ischaemic heart disease'

To see the other types of publications on this topic, follow the link: Ischaemic heart disease.

Author: Grafiati

Published: 4 June 2021

Last updated: 20 February 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Ischaemic heart disease.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shah, Dr Aashka M. "Fibrinogen and Ischaemic Heart Disease." International Journal of Scientific Research 3, no. 6 (June 1, 2012): 257–58. http://dx.doi.org/10.15373/22778179/june2014/81.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Saeid, Feyzizadeh, Javadi Aniseh, Badalzadeh Reza, and Vafaee S. Manouchehr. "Signaling mediators modulated by cardioprotective interventions in healthy and diabetic myocardium with ischaemia–reperfusion injury." European Journal of Preventive Cardiology 25, no. 14 (February 14, 2018): 1463–81. http://dx.doi.org/10.1177/2047487318756420.

Full text

Abstract:

Ischaemic heart diseases are one of the major causes of death in the world. In most patients, ischaemic heart disease is coincident with other risk factors such as diabetes. Patients with diabetes are more prone to cardiac ischaemic dysfunctions including ischaemia–reperfusion injury. Ischaemic preconditioning, postconditioning and remote conditionings are reliable interventions to protect the myocardium against ischaemia–reperfusion injuries through activating various signaling pathways and intracellular mediators. Diabetes can disrupt the intracellular signaling cascades involved in these myocardial protections, and studies have revealed that cardioprotective effects of the conditioning interventions are diminished in the diabetic condition. The complex pathophysiology and poor prognosis of ischaemic heart disease among people with diabetes necessitate the investigation of the interaction of diabetes with ischaemia–reperfusion injury and cardioprotective mechanisms. Reducing the outcomes of ischaemia–reperfusion injury using targeted strategies would be particularly helpful in this population. In this study, we review the protective interventional signaling pathways and mediators which are activated by ischaemic conditioning strategies in healthy and diabetic myocardium with ischaemia–reperfusion injury.

APA, Harvard, Vancouver, ISO, and other styles

3

Fox, K., and D. G. Julian. "Ischaemic heart disease." Current Opinion in Cardiology 1, no. 4 (July 1986): 451–52. http://dx.doi.org/10.1097/00001573-198607000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Julian, D. G., and K. Fox. "Ischaemic heart disease." Current Opinion in Cardiology 1, no. 6 (1986): 825–26. http://dx.doi.org/10.1097/00001573-198611000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

&NA;. "Ischaemic heart disease." Current Opinion in Cardiology 1, no. 6 (1986): 963–76. http://dx.doi.org/10.1097/00001573-198611000-00029.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Julian, D. G. "Ischaemic heart disease." Current Opinion in Cardiology 2, no. 6 (November 1987): 947–48. http://dx.doi.org/10.1097/00001573-198711000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Ischaemic heart disease." Current Opinion in Cardiology 3, no. 4 (July 1988): 561–651. http://dx.doi.org/10.1097/00001573-198803040-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Ischaemic heart disease." Current Opinion in Cardiology 3, no. 4 (July 1988): 561–651. http://dx.doi.org/10.1097/00001573-198807000-00012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Crouse, JohnR. "ISCHAEMIC HEART DISEASE." Lancet 341, no. 8850 (April 1993): 931–32. http://dx.doi.org/10.1016/0140-6736(93)91218-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Peters, David, P. G. F. Nixon, Wayne Perry, and Val Hopwood. "Ischaemic heart disease." Complementary Therapies in Medicine 2, no. 1 (January 1994): 14–20. http://dx.doi.org/10.1016/0965-2299(94)90154-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

HANSEN, BIRGIT FISCHER. "ISCHAEMIC HEART DISEASE." Acta Pathologica Microbiologica Scandinavica Series A :Pathology 90A, no. 1-6 (August 19, 2009): 37–49. http://dx.doi.org/10.1111/j.1699-0463.1982.tb00061_90a.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Fryearson, John, and Dawn L. Adamson. "Heart disease in pregnancy: Ischaemic heart disease." Best Practice & Research Clinical Obstetrics & Gynaecology 28, no. 4 (May 2014): 551–62. http://dx.doi.org/10.1016/j.bpobgyn.2014.03.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "Ischaemic heart disease I." Current Opinion in Cardiology 1, no. 4 (July 1986): 555–78. http://dx.doi.org/10.1097/00001573-198607000-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Fox, K., and D. G. Julian. "Ischaemic heart disease Overview." Current Opinion in Cardiology 2, no. 4 (July 1987): 569–70. http://dx.doi.org/10.1097/00001573-198707000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Ischaemic heart disease II." Current Opinion in Cardiology 2, no. 6 (November 1987): 1077–110. http://dx.doi.org/10.1097/00001573-198711000-00021.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Fuster, V., and D. G. Julian. "Ischaemic heart disease Overview." Current Opinion in Cardiology 3, no. 4 (July 1988): 459–60. http://dx.doi.org/10.1097/00001573-198803040-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Fuster, V., and D. G. Julian. "Ischaemic heart disease Overview." Current Opinion in Cardiology 3, no. 4 (July 1988): 459–60. http://dx.doi.org/10.1097/00001573-198807000-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Abergel, E., Y. Bernard, E. Brochet, C. Chauvel, A. Cohen, B. Cormier, J. F. Forissier, et al. "Chronic ischaemic heart disease." Archives of Cardiovascular Diseases 101, no. 4 (April 2008): 271–77. http://dx.doi.org/10.1016/s1875-2136(08)73704-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Bell, Robert M. "Remote ischaemic conditioning and ischaemic heart disease." British Journal of Hospital Medicine 75, Sup1 (January 2014): C13—C16. http://dx.doi.org/10.12968/hmed.2014.75.sup1.c13.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Iung, B. "VALVE DISEASE: Interface between valve disease and ischaemic heart disease." Heart 84, no. 3 (September 1, 2000): 347–52. http://dx.doi.org/10.1136/heart.84.3.347.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Haines, A. "Psychological characteristics and fatal ischaemic heart disease." Heart 85, no. 4 (April 1, 2001): 385–89. http://dx.doi.org/10.1136/heart.85.4.385.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Rasmiena, Aliki A., Theodore W. Ng, and Peter J. Meikle. "Metabolomics and ischaemic heart disease." Clinical Science 124, no. 5 (November 12, 2012): 289–306. http://dx.doi.org/10.1042/cs20120268.

Full text

Abstract:

Ischaemic heart disease accounts for nearly half of the global cardiovascular disease burden. Aetiologies relating to heart disease are complex, but dyslipidaemia, oxidative stress and inflammation are cardinal features. Despite preventative measures and advancements in treatment regimens with lipid-lowering agents, the high prevalence of heart disease and the residual risk of recurrent events continue to be a significant burden to the health sector and to the affected individuals and their families. The development of improved risk models for the early detection and prevention of cardiovascular events in addition to new therapeutic strategies to address this residual risk are required if we are to continue to make inroads into this most prevalent of diseases. Metabolomics and lipidomics are modern disciplines that characterize the metabolite and lipid complement respectively, of a given system. Their application to ischaemic heart disease has demonstrated utilities in population profiling, identification of multivariate biomarkers and in monitoring of therapeutic response, as well as in basic mechanistic studies. Although advances in magnetic resonance and mass spectrometry technologies have given rise to the fields of metabolomics and lipidomics, the plethora of data generated presents challenges requiring specific statistical and bioinformatics applications, together with appropriate study designs. Nonetheless, the predictive and re-classification capacity of individuals with various degrees of risk by the plasma lipidome has recently been demonstrated. In the present review, we summarize evidence derived exclusively by metabolomic and lipidomic studies in the context of ischaemic heart disease. We consider the potential role of plasma lipid profiling in assessing heart disease risk and therapeutic responses, and explore the potential mechanisms. Finally, we highlight where metabolomic studies together with complementary -omic disciplines may make further inroads into the understanding, detection and treatment of ischaemic heart disease.

APA, Harvard, Vancouver, ISO, and other styles

23

Silverdal, Jonas, Helen Sjöland, Entela Bollano, Aldina Pivodic, Ulf Dahlström, and Michael Fu. "Prognostic impact over time of ischaemic heart disease vs. non‐ischaemic heart disease in heart failure." ESC Heart Failure 7, no. 1 (January 7, 2020): 265–74. http://dx.doi.org/10.1002/ehf2.12568.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sheridan, J. V., P. Thomas, and D. J. Sheridan. "Felodipine in Ischaemic Heart Disease." Drugs 34, Supplement 3 (1987): 71–78. http://dx.doi.org/10.2165/00003495-198700343-00016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Mahmood, Manzoor, Md Harisul Hoque, SA Mahmood, Mohammad Abdul Quayum, Jahanara Arzu, and Kazi Sharmin Rahman. "Prevention of Ischaemic Heart Disease." University Heart Journal 10, no. 1 (August 20, 2015): 27–30. http://dx.doi.org/10.3329/uhj.v10i1.24594.

Full text

Abstract:

Prevention strategies are based on identification and modulation of cardiovascular risk factors. Targeting high risk individuals is cost-effective. More relevant to the practising clinicians is Identification of those individuals in whom intervention (life style or pharmacological) will prevent cardiovascular events (fatal and non-fatal myocardial infarction) and/or the need for interventional or surgical procedures, extending duration and quality of life (QOL). Modification of reversible risk factors (rather than interventional procedures) has been largely responsible for the decline in age-adjusted cardiovascular mortality.University Heart Journal Vol. 10, No. 1, January 2014; 27-30

APA, Harvard, Vancouver, ISO, and other styles

26

Prichard, B. N. C. "Carvedilol in Ischaemic Heart Disease." Cardiology 82, no. 3 (1993): 34–39. http://dx.doi.org/10.1159/000175932.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

WOOD, D. A. "AETIOLOGY OF ISCHAEMIC HEART DISEASE." British Journal of Anaesthesia 61, no. 1 (July 1988): 3–10. http://dx.doi.org/10.1093/bja/61.1.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Gershlick, A. H. "Platelets and ischaemic heart disease." Current Opinion in Cardiology 1, no. 4 (July 1986): 453–64. http://dx.doi.org/10.1097/00001573-198607000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Meade, T. W. "Fibrinogen in Ischaemic Heart Disease." European Heart Journal 16, suppl A (March 2, 1995): 31–35. http://dx.doi.org/10.1093/eurheartj/16.suppl_a.31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sleight, Peter. "Smoking and Ischaemic Heart Disease." European Journal of Cardiovascular Risk 6, no. 5 (October 1999): 285–86. http://dx.doi.org/10.1177/204748739900600501.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Cauldwell, Matthew, Lucia Baris, Jolien W. Roos-Hesselink, and Mark R. Johnson. "Ischaemic heart disease and pregnancy." Heart 105, no. 3 (November 15, 2018): 189–95. http://dx.doi.org/10.1136/heartjnl-2018-313454.

Full text

Abstract:

Although ischaemic heart disease is currently rarely encountered in pregnancy, occurring between 2.8 and 6.2 per 100 000 deliveries, it is becoming more common as women delay becoming pregnant until later life, when medical comorbidities are more common, and because of the higher prevalence of obesity in the pregnant population. In addition, chronic inflammatory diseases, which are more common in women, may contribute to greater rates of acute myocardial infarction (AMI). Pregnancy itself seems to be a risk factor for AMI, although the exact mechanisms are not clear. AMI in pregnancy should be investigated in the same manner as in the non-pregnant population, not allowing for delays, with investigations being conducted as they would outside of pregnancy. Maternal morbidity following AMI is high as a result of increased rates of heart failure, arrhythmia and cardiogenic shock. Delivery in women with history of AMI should be typically guided by obstetric indications not cardiac ones.

APA, Harvard, Vancouver, ISO, and other styles

32

De Cristofaro, R. "Anticoagulation in ischaemic heart disease." Heart 92, no. 8 (August 1, 2006): 1011–12. http://dx.doi.org/10.1136/hrt.2005.085555.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Currie, C. J., P. Conway, and C. D. Poole. "Ischaemic heart disease in men." Heart 93, no. 11 (November 1, 2007): 1471. http://dx.doi.org/10.1136/hrt.2007.130567.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Mensah, G. A. "Ischaemic heart disease in Africa." Heart 94, no. 7 (July 1, 2008): 836–43. http://dx.doi.org/10.1136/hrt.2007.136523.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Pocock, Mamatha O., Lucy Dorrell, and Paola Cicconi. "Pathophysiology of ischaemic heart disease." Current Opinion in HIV and AIDS 12, no. 6 (November 2017): 548–53. http://dx.doi.org/10.1097/coh.0000000000000411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Lindop, G. "Non-atherosclerotic Ischaemic Heart Disease." Histopathology 16, no. 3 (March 1990): 313. http://dx.doi.org/10.1111/j.1365-2559.1990.tb01125.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Burr, Michael L. "Alcohol and Ischaemic Heart Disease." Journal of the Royal Society of Health 114, no. 4 (August 1994): 216–18. http://dx.doi.org/10.1177/146642409411400411.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Meade, T. W. "Thrombosis and ischaemic heart disease." Heart 53, no. 5 (May 1, 1985): 473–76. http://dx.doi.org/10.1136/hrt.53.5.473.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Beulens, Joline WJ, and Henk FJ Hendriks. "Alcohol and ischaemic heart disease." Lancet 367, no. 9514 (March 2006): 902. http://dx.doi.org/10.1016/s0140-6736(06)68377-3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Fleck, A. "LATITUDE AND ISCHAEMIC HEART DISEASE." Lancet 333, no. 8638 (March 1989): 613. http://dx.doi.org/10.1016/s0140-6736(89)91634-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Jokhi, Percy, and Nicholas Curzen. "Ischaemic heart disease: stable angina." Medicine 38, no. 8 (August 2010): 414–20. http://dx.doi.org/10.1016/j.mpmed.2010.05.007.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Whittaker, Andrew, Percy Jokhi, and Nicholas Curzen. "Ischaemic heart disease: stable angina." Medicine 42, no. 9 (September 2014): 495–501. http://dx.doi.org/10.1016/j.mpmed.2014.06.016.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Gabara, Lavinia, Percy Jokhi, and Nick Curzen. "Ischaemic heart disease: stable angina." Medicine 46, no. 9 (September 2018): 520–27. http://dx.doi.org/10.1016/j.mpmed.2018.06.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Bondagji, Nabeel S. "Ischaemic heart disease in pregnancy." Journal of the Saudi Heart Association 24, no. 2 (April 2012): 89–97. http://dx.doi.org/10.1016/j.jsha.2011.12.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Segall, JeffreyJ. "LATITUDE AND ISCHAEMIC HEART DISEASE." Lancet 333, no. 8647 (May 1989): 1146. http://dx.doi.org/10.1016/s0140-6736(89)92430-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Sinclair, Hugh. "LATITUDE AND ISCHAEMIC HEART DISEASE." Lancet 333, no. 8643 (April 1989): 895. http://dx.doi.org/10.1016/s0140-6736(89)92880-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Shahar, Eyal. "Antioxidants and ischaemic heart disease." Lancet 350, no. 9078 (August 1997): 667. http://dx.doi.org/10.1016/s0140-6736(05)63362-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Leo, Maria A., and Charles S. Lieber. "Antioxidants and ischaemic heart disease." Lancet 350, no. 9078 (August 1997): 667. http://dx.doi.org/10.1016/s0140-6736(05)63363-6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Violi, Francesco, and Luigi Iullano. "Antioxidants and ischaemic heart disease." Lancet 350, no. 9078 (August 1997): 667–68. http://dx.doi.org/10.1016/s0140-6736(05)63364-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Rapola, Janne M., Jarmo Virtamo, and Jussi K. Huttunen. "Antioxidants and ischaemic heart disease." Lancet 350, no. 9078 (August 1997): 668. http://dx.doi.org/10.1016/s0140-6736(05)63365-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!